ALX Oncology (ALXO) Q3 2026 earnings review
ALX Oncology delays key trial results, and its spending rises
ALX Oncology, a cancer drug developer with no products on sale, stepped up trial spending while its main study slipped later. By our math, research costs rose 17% from a year ago, excluding last year's one-off payment, because more patients joined its trials. Chief executive Jason Lettmann now expects breast cancer results in the second half of 2027, from about 120 patients.
| Quarterly loss | $21.8M $22.1M a year ago |
|---|---|
| Research spending, excluding last year's one-off payment | +17% from a year ago, by our math |
| Cash and investments | $147.2M $153.4M three months earlier |
| Funding outlook | Unchanged cash lasts through the first half of 2028 |
โ๏ธ Verdict: ๐ด Bearish
The story got worse because the breast cancer study, the main test of lead drug evorpacept, now reports later than planned. Evorpacept blocks CD47, a protein cancer cells use to hide from immune cells. The good news: ALX2004, its second drug, keeps its December date and adds early signs of whether it works.
The question now is whether ALX2004 can become a second drug worth funding before the breast cancer data arrives. Clear tumor shrinkage with mild side effects would spread the risk, but weak results would leave everything on evorpacept. December's webinar, covering 35 to 40 patients, will tell.
๐ Bull Case
First ALX2004 Results Will Include Tumor Response
ALX2004, the second drug from ALX Oncology, carries a cell-killing payload to tumor cells displaying the EGFR protein. Chief executive Jason Lettmann said it has "the potential to address a broad range of EGFR-expressing solid tumors".
The developer named December, inside the second-half window it set in March, and the results will include early signs of whether the drug works. A webinar will "review the safety and efficacy results from 35-40 patients enrolled to date".
This matters because a second drug spreads the risk now resting on evorpacept, the lead drug. But early doses across a few dozen patients give only a first read, so one webinar cannot settle the case.
What to watch: whether the December webinar names a dose for the next trial stage. Mild side effects at that dose would give the developer a second drug ready for larger trials.
Nature Medicine Publishes the Stomach Cancer Trial
Evorpacept, the lead drug of ALX Oncology, blocks CD47, a protein cancer cells use to hide from immune cells. In September, Nature Medicine published ASPEN-06, which tested evorpacept with standard drugs in stomach cancer driven by HER2, a growth protein.
Chief executive Jason Lettmann said the paper "further reinforces the promise of evorpacept and our biomarker-driven development strategy". Peer review in a leading journal makes the CD47 finding harder to dismiss as chance.
But the paper repeats data ALX Oncology first showed in November 2025, and the high-CD47 group held only 43 patients.
What to watch: the share of breast cancer patients testing high for CD47, due in the second half of 2027. A share well below the half management expects would shrink the drug's market.
Positives this quarter didn't test
Four strengths behind the evorpacept case got no new evidence this quarter. Evorpacept, the lead drug of ALX Oncology, blocks CD47, a protein cancer cells use to hide from immune cells.
- Need after Enhertu, a leading HER2 drug: no standard treatment exists once breast cancer keeps growing on it; results in the second half of 2027 will test this.
- Lymphoma: with two standard drugs, evorpacept produced complete responses in 92% of untreated patients with a slow-growing blood cancer; a larger trial would move this.
- Safety: more than 750 patients have taken evorpacept; any new safety signal in the breast cancer trial would move this.
- Myeloma: Sanofi runs a trial adding evorpacept to its drug Sarclisa in a bone-marrow cancer; a Sanofi update would move this.
๐ป Bear Case
Breast Cancer Trial Results Move to Late 2027
ASPEN-09-Breast tests evorpacept, the lead drug of ALX Oncology, with standard HER2 drugs in breast cancer that has spread. Evorpacept blocks CD47, a protein cancer cells use to hide from immune cells. Chief executive Jason Lettmann said enrollment "remains robust".
Results will now come "from approximately 120 patients in the second half of 2027", Lettmann said. The release gives no reason for dropping the earlier plan.
- A year ago: interim results in the third quarter of 2026
- In March: results from the first 80 of up to 120 patients by mid-2027
- Now: one readout of the full trial, up to six months after the March date
This matters because the breast cancer trial is the first test of whether the stomach cancer result carries over. The release says enrollment "remains on track", yet the March plan now ends later. By our math, the results could arrive with only six months of planned funding left.
What to watch: whether ALX Oncology reports any early look at the trial before the second half of 2027. Another change of date would mean the enrollment claim and the schedule do not match.
Research Spending Rose a Third From Last Quarter
ALX Oncology has no sales, so investors' cash pays for its trials. Research spending reached $17.5 million, up 33% from the second quarter, because of "increased site activations and patient enrollment", the release said.
- Research spending excluding last year's one-off milestone payment: up 16.9% from a year ago, by our math
- Research staff costs: up 35.9% from a year ago
- Loss excluding one-offs: $18.9 million, up 32% from the second quarter
The filing warns that "our expenses will increase substantially", and this quarter shows it. By our math, cash now covers about eight quarters at the third quarter's loss rate, down from almost 11 at June's rate.
What to watch: fourth-quarter research spending, due in early 2027. Another rise this large would use cash faster than the funding plan allows, by our math.
Risks this quarter didn't answer
Five standing concerns about evorpacept, the lead drug that blocks the CD47 protein cancer cells use to hide, got no new numbers this quarter.
- Patient test: evorpacept needs an approved CD47 test; a partner is building one, with no update this quarter.
- CD47 cut-off: in March, management had not set the level that counts as high; breast cancer data should fix it.
- Stomach to breast: only the breast cancer trial, not comparisons with other drugs' trials, can show the stomach cancer result carries over.
- Survival: the filing gives a hazard ratio of 0.70, against 0.63 cited in November 2025; nearer 1 means less benefit.
- Rivals after Enhertu, a leading HER2 drug: no competitor news in the materials.
๐ Other Themes
Blackstone Funds Swapped Shares for Warrants
In October, funds tied to Blackstone, RA Capital and venBio handed back 13.4 million shares to ALX Oncology. In return they took pre-funded warrants, which convert into the same number of shares for a tenth of a cent each. The developer retired the returned shares. A holder cannot convert such warrants if it would then own more than 4.99% or 9.99% of the stock, the filing said.
๐ฒ Other KPIs
The weighted share count rose 163% from a year ago to 140.9 million, after the February share sale. In the third quarter ALX Oncology sold 4.3 million new shares through its at-the-market program, which sells stock gradually on the exchange. Counting pre-funded warrants, the total reached 156.4 million.
Interest income reached $1.4 million, up 72% from a year ago. In the second quarter it had risen 36%. The filing credits bigger cash and investment balances after the February share sale. Interest now offsets about 6% of quarterly operating costs.
Bills for trial work done but not yet paid reached $8.7 million, up 41% since December. The rise tracks the added trial sites and patients. Part of this year's trial cost will therefore turn into cash payments in later quarters.
๐ฎ Guidance
Unchanged. The release said cash should fund the plan through the first half of 2028. By our math, that leaves room for about $21 million of spending a quarter. The third quarter's loss rate sits inside that limit, with less room than in June. ALX Oncology can also draw another $20 million from its HSBC loan until June 2028.
Unchanged in timing, wider in content. ALX2004 is the drug that carries a cell-killing payload to tumors with the EGFR protein. The plan names December and adds early signs of whether it works to the safety data. A year ago these results were due in the first half of 2026; in March they moved to the second half.
Cut. The plan now waits for the whole trial instead of its first 80 patients, so results move past the mid-2027 date set in March. The release gives no reason. This breast cancer trial is the main test of evorpacept, the lead drug, so the change delays the most important evidence ALX Oncology expects.
New. The filing says overhead costs, mainly office staff, legal fees and insurance, will "remain stable for the remainder of this year". By our math, a fourth quarter at the third quarter's $5.5 million would sit 2% above a year earlier. Overhead rose 8% in the third quarter because ALX Oncology hired more staff, the release said.
โ Key Questions
Why did the 80-patient breast cancer readout disappear?
In March, ALX Oncology planned results from the first 80 patients by mid-2027. The release now points only to the full trial, without a reason. The answer shows whether enrollment speed or the data itself drove the change.
What CD47 level will count as high in breast cancer?
The cut-off decides how many patients evorpacept could treat. Management said in March it would use this trial to set the level, and that it expects about half of patients to test high.
Which ALX2004 doses will the December data cover?
In March, management called up to four dose levels a reasonable expectation by the time of the update. The number of patients on higher doses decides how much the webinar can say about whether the drug works.
Why lease new lab space after closing Palo Alto?
ALX Oncology shut its Palo Alto lab in June and paid $2.4 million to end that lease. In October it signed a South San Francisco lab and office sublease running to April 2030.
Will ALX Oncology draw the extra HSBC loan money?
The HSBC facility lets it borrow another $20 million through June 2028. Drawing it would stretch how long cash lasts, but the loan charges a floating rate of at least 6%.
